Literature DB >> 11309279

Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest.

G Niu1, K H Shain, M Huang, R Ravi, A Bedi, W S Dalton, R Jove, H Yu.   

Abstract

Gene therapy of B16 tumors with a dominant-negative signal transducer and activator of transcription (Stat3) variant, designated Stat3beta, results in inhibition of tumor growth and tumor regression. Although only 10-15% of the tumor cells are transfected in vivo, the Stat3beta-induced antitumor effect is associated with massive apoptosis of B16 tumor cells, indicative of a potent bystander effect. Here, we provide evidence that blocking Stat3 signaling in B16 cells results in release of soluble factors that are capable of inducing apoptosis and cell cycle arrest of nontransfected B16 cells. RNase protection assays using multi-template probes specific for key physiological regulators of apoptosis reveal that overexpression of Stat3beta in B16 tumor cells induces the expression of the apoptotic effector, tumor necrosis factor-related apoptosis-inducing ligand. These in vitro results suggest that the observed in vivo bystander effect leading to tumor cell growth inhibition is mediated, at least in part, by soluble factors produced as a result of overexpression of Stat3beta in tumor cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309279

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  STAT3 Knockdown in B16 Melanoma by siRNA Lipopolyplexes Induces Bystander Immune Response In Vitro and In Vivo.

Authors:  Aws Alshamsan; Samar Hamdy; Azita Haddadi; John Samuel; Ayman O S El-Kadi; Hasan Uludağ; Afsaneh Lavasanifar
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

2.  On safari to Random Jungle: a fast implementation of Random Forests for high-dimensional data.

Authors:  Daniel F Schwarz; Inke R König; Andreas Ziegler
Journal:  Bioinformatics       Date:  2010-05-26       Impact factor: 6.937

3.  Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity.

Authors:  Fengdong Cheng; Hongwei Wang; Pedro Horna; Zi Wang; Bijal Shah; Eva Sahakian; Karrune V Woan; Alejandro Villagra; Javier Pinilla-Ibarz; Said Sebti; Mitchell Smith; Jianguo Tao; Eduardo M Sotomayor
Journal:  Cancer Res       Date:  2012-06-22       Impact factor: 12.701

4.  Antitumorigenic potential of STAT3 alternative splicing modulation.

Authors:  Francesca Zammarchi; Elisa de Stanchina; Eirini Bournazou; Teerawit Supakorndej; Kathryn Martires; Elyn Riedel; Adriana D Corben; Jacqueline F Bromberg; Luca Cartegni
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

5.  Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy.

Authors:  Lee Spraggon; Luca Cartegni
Journal:  Drug Discov Today Ther Strateg       Date:  2013

Review 6.  Cytokine-induced tumor suppressors: a GRIM story.

Authors:  Dhan V Kalvakolanu; Shreeram C Nallar; Sudhakar Kalakonda
Journal:  Cytokine       Date:  2010-04-10       Impact factor: 3.861

7.  Proapoptotic and antiapoptotic actions of Stat1 versus Stat3 underlie neuroprotective and immunoregulatory functions of IL-11.

Authors:  Jingya Zhang; Yueting Zhang; Dipankar J Dutta; Azeb T Argaw; Virginie Bonnamain; Jeremy Seto; David A Braun; Andleeb Zameer; Fernand Hayot; Carolina B Lòpez; Cedric S Raine; Gareth R John
Journal:  J Immunol       Date:  2011-06-27       Impact factor: 5.422

8.  Role of Stat3 in regulating p53 expression and function.

Authors:  Guilian Niu; Kenneth L Wright; Yihong Ma; Gabriela M Wright; Mei Huang; Rosalyn Irby; Jon Briggs; James Karras; W Douglas Cress; Drew Pardoll; Richard Jove; Jiangdong Chen; Hua Yu
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

9.  STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain.

Authors:  Olga A Timofeeva; Nadya I Tarasova; Xueping Zhang; Sergey Chasovskikh; Amrita K Cheema; Honghe Wang; Milton L Brown; Anatoly Dritschilo
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-03       Impact factor: 11.205

10.  Characterization of STAT3 activation and expression in canine and human osteosarcoma.

Authors:  Stacey L Fossey; Albert T Liao; Jennifer K McCleese; Misty D Bear; Jiayuh Lin; Pui-Kai Li; William C Kisseberth; Cheryl A London
Journal:  BMC Cancer       Date:  2009-03-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.